Paperwork Reduction Act of 1995, the Health Care Financing Administration (HCFA), Department of Health and Human Services, has submitted to the Office of Management and Budget (OMB) the following proposals for the collection of information. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

1. *Type of Request:* Reinstatement, without change, of a previously approved collection for which approval has expired;

Title of Information Collection: State Medicaid Eligibility Quality Control Sampling Plan;

Form No.: HCFA–317;

Use: The State MEQC sampling plan is necessary for HCFA to monitor the States' operation of the MEQC system. The sampling plan includes all data involved in the States' sample selection process—population sizes and sample frame lists, sample sizes, sample selection procedures, and claims collection procedures;

Frequency: Annually;

Affected Public: State, local, or tribal government;

Number of Respondents: 55;

Total Annual Responses: 110;

Total Annual Hours: 2,640.

To request copies of the proposed paperwork collection referenced above, E-mail your request, including your address, to Paperwork@hcfa.gov, or call the Reports Clearance Office on (410) 786–1326. Written comments and recommendations for the proposed information collections should be sent within 60 days of this notice directly to the HCFA Paperwork Clearance Officer designated at the following address: HCFA, Office of Financial and Human Resources, Management Planning and Analysis Staff, Attention: Linda Mansfield, Room C2–26–17, 7500 Security Boulevard, Baltimore, Maryland 21244–1850.

Dated: February 5, 1996.

Kathleen B. Larson,

Director, Management Planning and Analysis Staff, Office of Financial and Human Resources, Health Care Financing Administration.

[FR Doc. 96–2956 Filed 2–9–96; 8:45 am]

BILLING CODE 4120–03–P

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by contacting Robert Benson, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804 (telephone 301/496–7056 ext. 267; fax 301/402–0220). A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Attenuated Human Rotavirus Vaccine

Hoshino, Y., Kapikian, A.Z., and Chanock, R.M. (NIAID)
Filed 11 July 95 (priority to 11 Jul 94)
Serial No. 08/500,564 (CIP of 08/481,644)

Rotaviruses are recognized as the single most important etiologic agent of severe diarrhea in both developed and nondeveloped countries. This invention embodies an attenuated rotavirus as a vaccine. The claims of the invention relate to the generation of a cold-adapted virus that is not efficient in replication at normal human body temperatures and therefore may be capable of stimulating an immune response without causing illness. In a limited clinical trial, administration of a cold-adapted rotavirus vaccine to 26 adults demonstrated that the vaccine was safe, attenuated, and was capable of inducing a virus-specific serologic response. This invention has been PCT filed on July 11, 1995. (portfolio: Infectious Diseases—Vaccines, viral, non-AIDS)

Method for Generating Influenza A Viruses Bearing Attenuating Mutations in Internal Protein Genes

Murphy, B., Subbarao, K.E., Kawaoka, Y. (NIAID)
Filed 7 Jun 95
Serial No. 08/481,631 (CIP of 08/309,521, CIP of 08/123,933)

This invention describes a method of producing attenuated Influenza A strains for use as live Influenza A virus vaccine candidates. This method involves the introduction of three temperature-sensitive attenuating mutations into the polymerase basic protein 2 (PB2) gene of Influenza A virus. These mutations are introduced by site-directed mutagenesis at specific sites into a cDNA copy of the PB2 gene. An RNA transcript of this nutant PB2 gene is recovered into an infectious Influenza A virus using a host range restricted helper virus. This attending mutant PB2 gene can be transferred to each new variant of Influenza A virus as it appears in nature. The patent application covering this invention is available for licensing and contains claims to: The methods of producing the attenuated strains; the attenuated strains produced by the methods; and methods of vaccination using the attenuated strains. Viruses containing mutant PB2 genes are also available for licensing. (portfolio: Infectious Diseases—Vaccines, viral, non-AIDS)

Attenuated Influenza A Virus

Palese, P., Muster, T., Murphy, B.R., Enami, M., Bergmann, M., Subbaro, E.K., Chanock, R.M. (NIAID)
Filed 7 Jun 95 (priority to 3 Feb 92)
Serial No. 08/480,939 (FWC of 07/939,716)

This invention describes the development of a novel live attenuated influenza A virus for use in intranasal vaccines. This virus is unique in that it is a chimera of two influenza strains. This results in an attenuated virus capable of invoking an immune response and therefore protection against influenza. The claims of this invention cover a method for generating the attenuated influenza virus, introducing the viral construct into cell lines, and vaccinating a vertebrate with the attenated virus. Animal studies have demonstrated that infection with the chimeric virus leads to resistance to a challenge with wild-type virus. (portfolio: Infectious Diseases—Vaccines, viral, non-AIDS)

Pteridine Nucleotide Analogs as Fluorescent DNA Probes

Hawkins, M.E., Pfleiderer, W., Davis, M.D., Balis, F.M. (NCI)

Filed 26 May 95
Serial No. 08/451,641 (DIV of 08/245,923)

The invention concerns a series of pteridine deoxyribonucleotide analogs which are highly fluorescent and resemble purine nucleotides in chemical structure and properties. The phosphoramidite form of these fluorophores can be site-specifically incorporated into oligonucleotides using conventional DNA synthesis techniques. The fluorescence intensity of the pteridine nucleotide analogs is highly dependent on their physicochemical environment, thus making them ideal for the study of DNA-protein interactions. A real-time assay for HIV integrase has been developed using one of the pteridine nucleotide analogs that resembles guanosine. Other uses foreseen are as fluorescent labels for DNA probes and PCR primers and for investigating protein-DNA interactions. The claims include the phosphoramidite derivatives of the pteridine nucleotide analogs useful as starting materials for oligonucleotide synthesis and oligonucleotides incorporating the pteridine nucleotide analogs. (portfolio: Gene-Based Therapies—Research Tools and Reagents; Gene-Based Therapies—Diagnostics)

Dated: February 1, 1996.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 96–3073 Filed 2–9–96; 8:45 am]

BILLING CODE 4140–01–M

National Heart, Lung, and Blood Institute; Notice of a Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Heart, Lung, and Blood Special Emphasis Panel (SEP) meeting:

Name of SEP: Review of Tuberculosis Academic Award Applications.

Date: March 5, 1996.

Time: 9:00 a.m.

Place: Holiday Inn Chevy Chase, Chevy Chase, Maryland.

Contact Person: Louise P. Corman, Ph.D., Two Rockledge Center, Room 7180, 6701 Rockledge Drive, Bethesda, MD 20892–7924, (301) 435–0270.

Purpose/Agenda: To review and evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in sec. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health)

Dated: February 6, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96–3071 Filed 2–9–96; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings:

Name of Committee: National Diabetes and Digestive and Kidney Diseases Special Grants Review Committee, Subcommittee B.

Date: March 7–8, 1996.

Time: 5 p.m.–adjournment on March 8.

Place: Embassy Suites Hotel, 4300 Military Road, NW., Washington, DC 20015.

Contact Person: Ned Feder, Ph.D., Natcher Building, Room 6AS–25S, National Institutes of Health, Bethesda, Maryland 20892–6600, Phone: 301–594–8890.

Purpose/Agenda: To review and evaluate research grant applications.

Name of Committee: National Diabetes and Digestive and Kidney Diseases Special Grants Review Committee, Subcommittee C.

Date: February 29–March 1, 1996.

Time: 8:30 a.m.–adjournment.

Place: Stouffer Mayflower Hotel, 1127 Connecticut Ave., NW., Washington, DC 20036.

Contact Person: Daniel Matsumoto, Ph.D., Natcher Building, Room 6AS–37B, National Institutes of Health, Bethesda, Maryland 20892–6600, Phone: 301–594–8894.

Purpose/Agenda: To review and evaluate research grant applications.

Name of Committee: National Diabetes and Digestive and Kidney Diseases Special Grants Review Committee, Subcommittee D.

Date: March 1, 1996.

Time: 8 a.m.–adjournment.

Place: Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, Maryland 20815.

Contact Person: Ann A. Hagan, Ph.D., Natcher Building, Room 6AS–43G, National Institutes of Health, Bethesda, Maryland 20892–6600, Phone: 301–594–8891.

Purpose/Agenda: To review and evaluate research grant applications.

The meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program No. 93.847–849, Diabetes, Endocrine and Metabolic Diseases; Digestive Diseases and Nutrition; and Kidney Diseases, Urology and Hematology Research, National Institutes of Health)

Dated: February 6, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96–3072 Filed 2–9–96; 8:45 am]

BILLING CODE 4140–01–M

Prospective Grant of Exclusive License: Cartilage-Derived Morphogenetic Proteins

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license in the United States to practice the invention embodied in U.S. Public Health Service Employee Invention Report Number E–138–94/0 (PCT/US94/12814), entitled ''Cartilage-Derived Morphogenetic Proteins'' to Creative BioMolecules, Inc., having a place of business in Hopkinton, Massachusetts. The patent rights in this application have been assigned to the United States of America.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The present invention relates generally to the field of cartilage and bone development. More specifically, this invention relates to cartilage-derived morphogenetic proteins (CDMPs) that stimulate development and repair of cartilage *in vivo.* These proteins which exhibit chondrogenic properties are disclosed to be members of the TGF–B superfamily. Also disclosed are polynucleotides encoding two members of the CDMP family of proteins. Recombinant CDMP–1 protein was shown to have chondrogentic activity *in vivo.* The primary uses of this invention would be in orthopaedic reconstruction.